If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines. Check for active clinical trials using this agent.
Related Posts
Recent Posts
